Clot-busting drug improves survival for deadly form of stroke

Stephen FellerLOS ANGELES, Feb. 18 (UPI) -- Clot-busting drug Alteplase, used for heart attacks and non-bleeding strokes, can reduce disability and mortality in patients with a type of bleeding stroke.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news

Related Links:

Cerebral stroke is a leading cause of death and persistent disability of elderly in the world. Moreover, after the age of 55, the risk of stroke doubles with each passing decade. Of all strokes, approximately 85 percent are ischemic, caused by blockage of cerebral arteries and remaining hemorrhagic, caused by intracerebral or subarachnoid bleeding. Although stroke prevention by targeting several risk factors such as diabetes, smoking, sedentary lifestyle, hypertension, alcohol abuse and hyperlipidemia have decreased the stroke incidence, the total number of strokes is increasing due to the population aging. After an ischem...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
AbstractPurpose of reviewAs one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the stroke patient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group.Recent findingsSeveral recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for t...
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research
Authors: Campbell BC Abstract In recent years, reperfusion therapies such as intravenous thrombolysis and endovascular thrombectomy for ischaemic stroke have dramatically reduced disability and revolutionised stroke management. Thrombolysis with alteplase is effective when administered to patients with potentially disabling stroke, who are not at high risk of bleeding, within 4.5 hours of the time the patient was last known to be well. Emerging evidence suggests that other thrombolytics such as tenecteplase may be even more effective. Treatment may be possible beyond 4.5 hours in patients selected using brain imagi...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Maria R. Gancheva1*, Karlea L. Kremer1, Stan Gronthos2,3 and Simon A. Koblar1,3,4 1Stroke Research Programme Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia 2Mesenchymal Stem Cell Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia 3South Australian Health and Medical Research Institute, Adelaide, SA, Australia 4Central Adelaide Local Health Network, Adelaide, SA, Australia Stroke is a leading cause of permanent disability world-wide, but aside from rehabilitatio...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Emilio Rodríguez-Castro1,2, Manuel Rodríguez-Yáñez1,2, Susana Arias1,2, María Santamaría1,2, Iria López-Dequidt1,2, Ignacio López-Loureiro1, Manuel Rodríguez-Pérez1, Pablo Hervella1, Tomás Sobrino1, Francisco Campos1, José Castillo1* and Ramón Iglesias-Rey1* 1Clinical Neurosciences Research Laboratory, Department of Neurology, Clinical University Hospital, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain2Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
This study demonstrates that combination therapy is more effective than single therapy with either hUCBC or EPO for neurological recovery from subacute stroke. The common pathway underlying hUCBC and EPO treatment requires further study. Introduction Stroke, caused by the disruption of cerebral blood flow, is a leading cause of death and major disability throughout the world (1). However, the therapeutic options to deal with stroke are limited. Despite efforts to develop new therapies for stroke, all treatments have thus far failed to show a clinical effect or are known to have potential toxic effects. Although intra...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
ConclusionSSRI use was associated with a significant decrease in MACE rates compared with patients receiving mirtazapine. Bleeding risk was not affected by either antidepressant treatment. SSRIs may have cardioprotective benefits compared with mirtazapine.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Publication date: April 2019Source: The Lancet Neurology, Volume 18, Issue 4Author(s): Simiao Wu, Bo Wu, Ming Liu, Zhengming Chen, Wenzhi Wang, Craig S Anderson, Peter Sandercock, Yongjun Wang, Yining Huang, Liying Cui, Chuanqiang Pu, Jianping Jia, Tong Zhang, Xinfeng Liu, Suming Zhang, Peng Xie, Dongsheng Fan, Xunming Ji, Ka-Sing Lawrence Wong, Longde WangSummaryWith over 2 million new cases annually, stroke is associated with the highest disability-adjusted life-years lost of any disease in China. The burden is expected to increase further as a result of population ageing, an ongoing high prevalence of risk factors (eg, ...
Source: The Lancet Neurology - Category: Neurology Source Type: research
Update In March 2019, the American College of Cardiology (ACC) and the American Heart Association (AHA) released new guidelines that suggest that most adults without a history of heart disease should not take low-dose daily aspirin to prevent a first heart attack or stroke. Based on the ASPREE, ARRIVE, and ASCEND trials, the ACC/AHA guidelines concluded that the risk of side effects from aspirin, particularly bleeding, outweighed the potential benefit. The new guidelines do not pertain to people with established cardiovascular disease, in whom the benefits of daily aspirin have been found to outweigh the risks. ___________...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Heart Health Prevention Source Type: blogs
(American Heart Association) Rapidly lowering blood pressure beyond recommended targets safely reduced the risk of bleeding as a side effect in stroke patients but did not limit post-stroke disability.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Activase | Bleeding | Cardiology | Disability | Health | Heart | Stroke